Edition:
United States

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

48.79USD
3:49pm EDT
Change (% chg)

$1.27 (+2.67%)
Prev Close
$47.52
Open
$47.80
Day's High
$49.61
Day's Low
$47.49
Volume
482,083
Avg. Vol
799,530
52-wk High
$63.60
52-wk Low
$23.71

Select another date:

Tue, Mar 20 2018

BRIEF-Mark Stenhouse To Join Exact Sciences As President, Cologuard

* MARK STENHOUSE TO JOIN EXACT SCIENCES AS PRESIDENT, COLOGUARD

BRIEF-Exact Sciences Q4 Loss Per Share $0.18

* ANTICIPATES COMPLETED COLOGUARD TEST VOLUME OF 900,000-920,000 TESTS DURING 2018.

BRIEF-Exact Sciences announces upsize, pricing of $600 mln of 1 pct convertible senior notes due 2025

* EXACT SCIENCES ANNOUNCES UPSIZE AND PRICING OF $600 MILLION OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025

BRIEF-Exact Sciences Offers $500 Mln Convertible Senior Notes Due 2025

* EXACT SCIENCES ANNOUNCES OFFERING OF $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2025 Source text for Eikon: Further company coverage:

BRIEF-Exact Sciences Says "Comfortable" With Current 2018 Consensus Revenue Estimate Of Around $417 Mln

* EXACT SCIENCES CORP SAYS "COMFORTABLE" WITH CURRENT 2018 CONSENSUS REVENUE ESTIMATE OF AROUND $417 MILLION Source text for Eikon: Further company coverage:

BRIEF-Exact Sciences Says On Dec. 15, Co, Unit Entered Loan, Security Agreement For 24-Month Secured Revolving Credit Facility For Up To $15.0 Mln

* EXACT SCIENCES - ON DEC. 15, CO, UNIT ENTERED LOAN, SECURITY AGREEMENT FOR 24-MONTH SECURED REVOLVING CREDIT FACILITY FOR UP TO $15.0 MILLION - SEC FILING

BRIEF-Exact Sciences reports qtrly loss per share of $0.23

* Exact Sciences Corp qtrly loss per share $0.23; qtrly revenue $72.6 million, up 158 percent

Exact Sciences revenue beats on strong Cologuard volumes

Exact Sciences Corp reported quarterly revenue that blew past analysts' estimates as demand for the company's sole diagnostic test, Cologuard, more than doubled.

Exact Sciences revenue beats on strong Cologuard volumes

Oct 30 Exact Sciences Corp reported quarterly revenue that blew past analysts' estimates as demand for the company's sole diagnostic test, Cologuard, more than doubled.

Select another date: